Fibrosis-4 (FIB-4) Index for Liver Fibrosis
ورودیهای بالینی بیمار
حداقل ۱۸ — حداکثر ۱۲۰ • واحد: years
حداقل ۱ — حداکثر ۱۰۰۰۰ • واحد: U/L
حداقل ۱ — حداکثر ۱۰۰۰۰ • واحد: U/L
حداقل ۱ — حداکثر ۱۰۰۰ • واحد: 10⁹/L
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low risk0–1.45
- Indeterminate risk1.45–3.25
- High risk3.25–999999
The Fibrosis-4 (FIB-4) Index for Liver Fibrosis calculates assessing gastrointestinal disease severity, endoscopic intervention urgency, and rebleeding risk. Key inputs include age. Scores guide timing emergent endoscopy, initiating high-dose proton pump inhibitor infusions, or obtaining surgical consultation. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Non-invasive estimate of liver scarring in HCV and HBV patients, to assess need for biopsy. Calculated as (Age × AST) / (Platelet count × √ALT)
Clinical Indication
The Fibrosis-4 (FIB-4) Index for Liver Fibrosis is indicated for bedside clinical practice to support Non-invasive estimate of liver scarring in HCV and HBV patients, to assess need for biopsy. Calculated as (Age × AST) / (Platelet count × √ALT). It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with upper or lower gastrointestinal hemorrhage, acute pancreatitis, acute liver failure, or inflammatory bowel disease. Clinical application is indicated across Endoscopy suites, emergency GI triage, acute medical floors, and hepatology services.
Limitations & Contraindications
Initial hemoglobin values in hyperacute hemorrhage may falsely appear normal prior to complete extravascular-to-intravascular fluid equilibration. Clinical exclusion: Use with caution in patients <35 or >65 years old.
Clinical Pearls & Action Plan
Aggressive intravascular volume resuscitation and blood product support must precede diagnostic or therapeutic endoscopy.
FIB-4 = (Age × AST) / (Platelet count × √ALT)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| age | integer | Yes | Patient's age in years(years) |
| ast | float | Yes | Aspartate aminotransferase (AST) level(U/L) |
| alt | float | Yes | Alanine aminotransferase (ALT) level(U/L) |
| platelet_count | float | Yes | Platelet count in 10⁹/L(10⁹/L) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–1.45 | Low risk | Low risk of advanced fibrosis (F0-F1) |
| 1.45–3.25 | Indeterminate risk | Indeterminate risk (F2-F3) |
| 3.25–999999 | High risk | High risk of advanced fibrosis/cirrhosis (F3-F4) |
Evidence-Based References (EBM)
- Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006 Jun;43(6):1317-25. doi: 10.1002/hep.21178.DOI: 10.1002/hep.21178
- Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology. 2007 Jul;46(1):32-6. doi: 10.1002/hep.21669.DOI: 10.1002/hep.21669
- Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009 Oct;7(10):1104-12. doi: 10.1016/j.cgh.2009.05.033.DOI: 10.1016/j.cgh.2009.05.033